{"id":2205,"date":"2011-12-01T12:09:00","date_gmt":"2011-12-01T11:09:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2011\/teriflunomid-bei-multipler-sklerose-eine-plazebokontrollierte-studie"},"modified":"2011-12-01T12:09:00","modified_gmt":"2011-12-01T11:09:00","slug":"teriflunomid-bei-multipler-sklerose-eine-plazebokontrollierte-studie","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2011\/teriflunomid-bei-multipler-sklerose-eine-plazebokontrollierte-studie","title":{"rendered":"Teriflunomid bei Multipler Sklerose. Eine plazebokontrollierte Studie"},"content":{"rendered":"<p>Im N. Engl. J. Med. ist k\u00fcrzlich eine neue Studie zur Therapie der Multiplen Sklerose (MS) erschienen (1; vgl. auch 2, 3). Getestet wurde Teriflunomid gegen Plazebo. Teriflunomid ist der aktive Metabolit von Leflunomid, das f\u00fcr die Behandlung der Rheumatoiden Arthritis und ANCA-assoziierter Vaskulitiden zugelassen ist. Sanofi-Aventis, der Hersteller des Pr\u00fcfmedikaments, hat die Studie finanziell [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Im N. Engl. J. Med. ist k\u00fcrzlich eine neue Studie zur Therapie der Multiplen Sklerose (MS) erschienen (1; vgl. auch 2, 3). Getestet wurde Teriflunomid gegen Plazebo. Teriflunomid ist der aktive Metabolit von Leflunomid, das f\u00fcr die Behandlung der Rheumatoiden Arthritis und ANCA-assoziierter Vaskulitiden zugelassen ist. Sanofi-Aventis, der Hersteller des Pr\u00fcfmedikaments, hat die Studie finanziell [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[352,3116,3118,1409,4408,4407],"class_list":["post-2205","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-multiple-sklerose","tag-placebo","tag-plazebo","tag-studien","tag-temso-studie","tag-teriflunomid"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2205","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=2205"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2205\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=2205"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=2205"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=2205"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}